Life Science Investing CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Life Science Investing Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Life Science Investing Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Life Science Investing Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Life Science Investing Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
Life Science Investing Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
E-Power Resources Appoints New CEO and Expands Advisory Teams; Focus on Agressive Strategy for Tetepisca Graphite Project
Standard Uranium Receives Drill Permits and Initiates Ground Gravity Survey on the Corvo Uranium Project
